Telomir Pharmaceuticals Added to Membership of Russell 3000 and Russell Microcap Indexes

Telomir Pharmaceuticals Scientific Advisor to Participate in Drug Information Association 2024 Global Annual Meeting Panel

Telomir Pharmaceuticals Announces Two Pivotal Milestones for Lead Product Candidate Telomir-1

Telomir Pharmaceuticals Unveils Compelling Pre-clinical Data on Age-Reversal Drug Telomir-1 at National Press Club Event in Washington, D.C.

Telomir Pharmaceuticals’ Anti-Aging Expert and NYT Bestselling Author Michael F. Roizen, MD, to Present Promising Pre-Clinical Data for Age-Reversal Drug Telomir-1 at the National Press Club in Washington, DC, on April 15, 2024

UPDATE – Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on March 26th

Telomir Pharmaceuticals Uses AI Testing Models to Show its Lead Product Candidate’s Potential in DNA Age Reversal Science

Telomir Pharmaceuticals Presents Promising Pre-Clinical Data For Its Lead Development Product at Singapore Conference